Beam Therapeutics director Carole Ho to resign

Beam Therapeutics Inc. reported that Carole Ho has submitted her resignation from the company’s Board of Directors.

Accepted by SEC EDGAR 02/05/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beam Therapeutics Inc. reported that Carole Ho has submitted her resignation from the company’s Board of Directors. Her resignation is effective February 27, 2026, giving the company a short transition period to adjust its board composition.

The company states that Dr. Ho’s decision to resign did not result from any disagreement regarding Beam’s operations, policies, or practices. This indicates a voluntary board change rather than a response to a dispute or governance conflict.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Beam Therapeutics (BEAM) disclose in this 8-K?

Beam Therapeutics disclosed that board member Carole Ho has resigned from its Board of Directors. Her resignation is effective February 27, 2026, representing a planned governance change rather than an abrupt departure.

When is Carole Ho’s resignation from Beam Therapeutics’ board effective?

Carole Ho’s resignation from Beam Therapeutics’ Board of Directors is effective February 27, 2026. The notice of resignation was provided on January 31, 2026, allowing a brief transition period before the effective date.

Did Carole Ho resign from Beam Therapeutics due to a disagreement with the company?

No. Beam Therapeutics states that Dr. Ho’s decision to resign did not result from any disagreement with the company regarding its operations, policies, or practices. This characterizes the move as a non-conflict-related board change.

What type of SEC filing did Beam Therapeutics use to report the director resignation?

Beam Therapeutics reported the director resignation on a Form 8-K. This current report form is used to disclose significant corporate events, including changes in directors or certain officers and related governance matters.

Who signed the Beam Therapeutics 8-K reporting the board resignation?

The 8-K was signed on behalf of Beam Therapeutics by John Evans, the company’s Chief Executive Officer. His signature confirms the company’s authorization and validation of the disclosed board resignation information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000174599900017459992026-01-312026-01-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2026

Beam Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39208	81-5238376
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
238 Main Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 327-8775

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		BEAM		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the “Company”) with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026. Dr. Ho’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Beam Therapeutics Inc.
Date:	February 5, 2026	By:	/s/ John Evans
			John Evans Chief Executive Officer